Urethral carcinomas most frequently harbor alterations in TP53, PIK3CA, KDM6A, FGFR3, and ARID1A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KDM6A Mutation, and FGFR3 Mutation are the most common alterations in urethral carcinoma .
There are 8 clinical trials for urethral carcinoma, of which 7 are open and 1 is completed or closed. Of the trials that contain urethral carcinoma as an inclusion criterion, 4 are phase 1 (3 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).
ERBB2 and TP53 are the most frequent gene inclusion criteria for urethral carcinoma clinical trials .
Atezolizumab, nivolumab, and placebo are the most common interventions in urethral carcinoma clinical trials.
Significant Genes in Urethral Carcinoma
ERBB2 is an inclusion eligibility criterion in 2 clinical trials for urethral carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and urethral carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.